Clinical Trials Logo

Liver Metastases clinical trials

View clinical trials related to Liver Metastases.

Filter by:

NCT ID: NCT03803436 Recruiting - Neoplasms Clinical Trials

Improving Outcome of Selected Patients With Non-resectable Hepatic Metastases From Colo-rectal Cancer With Liver Transplantation

Start date: January 2, 2019
Phase: Phase 2
Study type: Interventional

The COLT trial is an investigator-driven, multicenter, non-randomized, open-label, controlled, prospective, parallel trial, aimed at assessing the efficacy (in terms of overall survival: OS) of liver transplantation (LT) in liver-only CRC metastases, compared with a matched cohort of patients bearing the same tumor characteristics, collected during the same time period and included in a phase III Italian RCT on triplet chemotherapy+antiEGFR

NCT ID: NCT03781934 Recruiting - Clinical trials for Hepatocellular Carcinoma

A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations

Start date: September 5, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicentre, open-label study to assess safety and tolerability of MIV-818 in patients with various solid tumours that have spread to the liver, or alternatively originating in the liver.

NCT ID: NCT03757858 Recruiting - Cancer Clinical Trials

Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases

Start date: March 1, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

It is a non-randomized pilot study.The allocation will be determined by patients or their immediate family members who were cooperative with physician's interpretations on the disease progression and updated information of cutting of edge treatment, the financial affordability, availability of treatment plans, possible tolerance or risks etc.The purpose of this study is to investigate the clinical efficacy and toxicity of autologous cellular immunotherapy combined with hyperthermia in abdominal and pelvic malignancies or metastases patients. Furthermore, to characterize response to different regimens,the investigators intent to explore the predictive and prognostic biomarker, as well as the changes in immune repertoire.

NCT ID: NCT03744624 Recruiting - Clinical trials for Hepatocellular Carcinoma

Application of 3D Printing in Laparoscopic Surgery of Liver Tumors

Start date: April 28, 2017
Phase: N/A
Study type: Interventional

To explore the utility of personalized 3D printed liver models in planning and navigating laparoscopic resections.

NCT ID: NCT03741088 Recruiting - Clinical trials for Carcinoma, Hepatocellular

Study to Evaluate VORTX Rx (Theresa)

Start date: March 21, 2018
Phase: N/A
Study type: Interventional

Multi-center, Open-labeled, Non-randomized Study to Evaluate the Acute Technical Performance and Safety Profile of the VORTX Rx® for Ablation of Primary and Metastatic Liver Tumors

NCT ID: NCT03697044 Not yet recruiting - Liver Metastases Clinical Trials

Irinotecan Drug-eluting Bead Liver Embolisation Registry

Start date: January 2019
Study type: Observational [Patient Registry]

Purpose: The purpose of this study is: to assess and define the current practice of the delivery of irinotecan loaded drug eluting beads in the treatment of liver metastases from colorectal cancer; to correlate how the delivery of this drug compares to worldwide/European guidelines, and to determine which individual variations in delivery may be associated with an increased complication profile or better outcome. The aim of the study is to: 1. Prospectively evaluate the number of centres providing DEBIRI 2. To determine the number of patients being treated nationally per year 3. To evaluate individual variations in practice with respect to number of treatments, method of pain control, side effect profile, and complication profile. 4. To collect patient specific data subsets to allow correlation and causal associations between these individual variations, and relate these to efficacy and survival during the study period.

NCT ID: NCT03689231 Active, not recruiting - Clinical trials for Neuroendocrine Tumors

Volumetric Imaging Follow up of Patients With Liver Metastases of Small Intestinal Neuroendocrine Tumors (NETs).

Start date: March 1, 2018
Study type: Observational

More than 50% of intestinal NETs are metastatic at the time of diagnosis, the liver being the main affected organ in 50-90% of cases. Initial liver tumor burden and slope of the tumor growth rate are two major prognostic factors in patients with intestinal NETs, followed by tumor grade at pathology. They are used in routine practice by oncologists to adapt patient treatment. Unlike other tumors, most NETs metastases are slow-growing tumors. Previous studies have shown that approximately half of the patients diagnosed with liver metastases showed no progression over a period of 3 to 6 months. The aim of this non randomised retrospective cohort study is to investigate whether the volumetric monitoring of the total tumor burden compared to the RECIST 1.1 criteria (used in routine practice by radiologists) at baseline and early follow-up (3 to 6 months) is more suitable for NETs, making possible to predict the prognosis at the onset of the disease, and also allowing a better adaptation of the treatment. The secondary objectives are to evaluate if the initial volume of the liver tumor is a prognostic factor of time to progression, to correlate the initial liver tumor volume and the number of liver lesions to the blood concentration of Chromogranin A (CgA), the presence of extra-abdominal disease and to correlate the tumor growth rate (TGR) and KI 67 (%) at base-line.

NCT ID: NCT03687853 Enrolling by invitation - Liver Metastases Clinical Trials

Application of Intrahepatic Arterial Infusion Chemotherapy for Patients With High Risk of Liver Metastases After Pancreatic Cancer Surgery

Start date: January 1, 2017
Phase: N/A
Study type: Interventional

Clinical results on intra-arterial adjuvant chemotherapy for prevention of liver metastasis following curative resection of pancreatic cancer

NCT ID: NCT03678428 Not yet recruiting - Clinical trials for Metastatic Colorectal Cancer

FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM

Start date: October 31, 2018
Phase: Phase 3
Study type: Interventional

The aim of the trial is to compare the objective response rates of FUDR/Oxaliplatin HAI plus CPT-11 and FOLFOXIRI chemotherapy in patients with initially non-resectable metastatic colorectal cancer liver metastases. The patients will be treated with systemic FOLFOXIRI chemotherapy or FUDR/Oxaliplatin hepatic arterial infusion with CPT-11 systemic chemotherapy.

NCT ID: NCT03654131 Recruiting - Liver Metastases Clinical Trials

Stereotactic Body Radiation Therapy vs. Percutaneous Microwave Ablation for Colorectal Cancer Patients With Metastatic Disease in the Liver

Start date: July 25, 2018
Phase: Phase 2
Study type: Interventional

This study is a randomized phase II trial between microwave ablation (MWA) and stereotactic body radiotherapy (SBRT) - two standard treatment modalities for colorectal patients with metastatic disease in the liver. Primary endpoint is freedom form local lesion progression.